Browsing tag:

Alzheimers disease


The approval of Aricept fifteen years ago was the last time there was anything new to treat the symptoms of Alzheimer’s disease. This lack of research and drug development is unnerving to patients and practitioners alike, with this lethal disease affecting 5.4 million Americans. On June 13, 2013 the BCC posted an alarming research report,[…]

Read More

Estimated Number of Cases of AD in the U.S. (millions). A report issued from the University of Washington in Seattle on March 5, 2013 revealed a startling statistic. The fastest growing health threat to Americans is not cancer or heart disease – it is Alzheimers disease! While this may not have been surprising information to[…]

Read More

Memantine Hydrochloride, CAS number 41100-52-1, is an effective oral medication for treating patients with Alzheimer’s disease. LGM Pharma can provide the Memantine Hydrochloride TEVA API for compounding purposes in the US, and offers a full range of support and services to it’s clients. Memantine is the first in a new and formidable class of Alzheimer’s[…]

Read More

Donepezil, CAS number 120014-06-4, is also marketed under the brand name Aricept, and is used in treatment of Alzheimer’s disease. Patients with dementia have low levels of the brain chemical acetylcholine, which is a crucial chemical for thinking and memory issues. Donepezil improves the patient’s nerve cell functioning by inhibiting the breakdown of acetylcholine. Aricept,[…]

Read More

Treating cutaneous T-cell lymphoma (CTCL) with a powerful drug that is safe and effective is essential. Bexarotene is a formidable treatment for those patients with CTCL, especially the patients who have found other treatments unsuccessful. Classified as a Retinoid, Bexarotene works to stop the growth of cancer cells. Bexarotene, CAS number 153559-49-0, is also known[…]

Read More